https://orcid.org/0000-0003-4795-1834
References
- Toumi M, Dabbous O, Aballéa S, et al. Recommendations for economic evaluations of cell and gene therapies: a systematic literature review with critical appraisal. Expert Rev Pharmacoecon Outcomes Res. 2023;23(5):483–497. doi: 10.1080/14737167.2023.2197214
- DiStefano MJ, Zemplenyi A, Anderson KE, et al. Alternative approaches to measuring value: an update on innovative methods in the context of the United States Medicare drug price negotiation program. Expert Rev Pharmacoecon Outcomes Res. 2023;24(2):171–180. doi: 10.1080/14737167.2023.2283584
- Oh M, McBride A, Bhattacharjee S, et al. The economic value of knowing BRCA status: universal BRCA testing for breast cancer prevention. Expert Rev Pharmacoecon Outcomes Res. 2023;23(3):309–316. doi: 10.1080/14737167.2023.2169135
- Oh M, McBride A, Bhattacharjee S, et al. The economic value of knowing BRCA status: BRCA testing for optimizing treatment in recurrent epithelial ovarian cancer. Expert Rev Pharmacoecon Outcomes Res. 2023;23(3):317–325. doi: 10.1080/14737167.2023.2169136
- Oh M, McBride A, Bhattacharjee S, et al. Economic value of knowing BRCA status: BRCA testing for prostate cancer prevention and optimal treatment. Expert Rev Pharmacoecon Outcomes Res. 2023;23(3):297–307. doi: 10.1080/14737167.2023.2169137
- Wiedmann L, Cairns J. Review of economic modeling evidence from NICE appraisals of rare disease treatments for spinal muscular atrophy. Expert Rev Pharmacoecon Outcomes Res. 2023;23(5):469–482. doi: 10.1080/14737167.2023.2193690
- National Institute for Health and Care Excellence (NICE). Final appraisal document: nusinersen for treating spinal muscular atrophy [TA588]. 2019 Jul [cited 2023 Dec 30]. Available from: https://www.nice.org.uk/guidance/ta588/documents/final-appraisaldetermination-document-2
- Gafni A, Birch S. Incremental cost-effectiveness ratios (ICERs): the silence of the lambda. Soc Sci Med. 2006;62(9):2091–2100. doi: 10.1016/j.socscimed.2005.10.023
- Drummond MF, Sculpher MJ, Claxton K, et al. Methods for the economic evaluation of health care programmes. 4th ed. Oxford: Oxford University Press; 2015.
- Wolters S, de Jong LA, Jansen C, et al. Differences in evidentiary requirements for oncology drug effectiveness assessments among six European health technology assessment bodies — can alignment be improved? Expert Rev Pharmacoecon Outcomes Res. 2024;24(2):251–265. doi: 10.1080/14737167.2023.2263166